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Objective. To quantifying the interdependency within the regulatory environment governing human subject research, including Institutional Review Boards (IRBs),
federally mandated Medicare coverage analysis and contract negotiations.
Methods. Over 8000 IRB, coverage analysis and contract applications initiated between 2013 and 2016 were analyzed using traditional and machine learning analytics
for a quality improvement effort to improve the time required to authorize the start of human research studies.
Results. Staffing ratios, study characteristics such as the number of arms, source of funding and number and type of ancillary reviews significantly influenced the
timelines. Using key variables, a predictive algorithm identified outliers for a workflow distinct from the standard process. Improved communication between
regulatory units, integration of common functions, and education outreach improved the regulatory approval process.
Conclusions. Understanding and improving the interdependencies between IRB, coverage analysis and contract negotiation offices requires a systems approach and
might benefit from predictive analytics.
Received 10 October 2017; Revised 1 March 2018; Accepted 30 March 2018
Key words: Common metrics, Institutional Review Board, best practices,
clinical trials, quality improvement.
Introduction
A central goal of the Clinical and Translational Science Awards (CTSA)
initiative is to foster data-driven improvements in medical research
infrastructure that “…increase the quality and efficiency of transla-
tional research, particularly of multisite trials.” [1] Local Institutional
Review Boards (IRBs) have garnered much of this focus in numerous
commission, federal agencies, and publications [2–11]. For example, a
recent publication explored IRB performance across 5 University of
California Schools of Medicine and proposed a model in which the
interaction between operational conditions, study characteristics and
proposal characteristics determines how quickly proposals are likely
to be approved [11]. The multitude of studies have led to reform
proposals have included centralizing IRBs [12], increasing federal
oversight, credentialing, greater training [10, 13], and increasing
resources for personnel and technology [14]. Furthermore, the time
required to acquire IRB approval is now a core “common metric” for
all CTSA-funded institutions [15].
However, local IRB’s do not operate in isolation but rather function
within a larger regulatory environment (see supplementary Figure A)
[11, 16–19]. For example, an IRB-approved informed consent form
(ICF) must inform a subject about their potential financial liability. That
financial responsibility is negotiated between the contracting unit, the
investigator and the sponsoring agency. The terms of that contract are,
in turn, reviewed by the institution’s Medicare billing coverage analysis
unit to assure compliance with the Centers for Medicare and Medicaid
Services regulations. All 3 units have different regulatory oversight for
the same section of the consent form and must coordinate their
respective language before the consent can be released and a study
initiated.
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The University of California at San Diego (UCSD) Altman Clinical and
Translational Research Institute has prioritized improving the perfor-
mance of the human research regulatory environment. This effort led
to the creation of theWorkflow, Outcomes and Quality Improvement
Office, which collects and analyzes operational data, conducts
data-driven quality improvement (QI) studies and modifies the work-
flows of regulatory offices. The present study is a novel approach
through the systems analysis to explore the relationship between
the various offices and identifies actionable data that can improve
performance.
Methods
Data Collection and Analysis
This process adhered to the International Council on Systems Engi-
neering Standards (INCOSE) QI [20]. Systems engineering is based on
the fundamental principle that the world is composed of inter-related
systems such that improvement in any one system requires under-
standing both the nature of that component and the environment
within which it exists. INCOSE QI standards are highly detailed,
incremental, iterative and flow through a series of prescribed steps
from project planning, project assessment, project control, decision
making, data analysis, through alternative strategy risk and opportunity
assessment to data analysis/modeling, exploring alternatives to the
“AS-IS” state, pilot testing and re-assessment.
Each stage begins with a declaration of the “customer’s” requirements, in
our case—to understand and improve the regulatory environment for
clinical research at UCSD. This methods and analysis are an example of
how INCOSE QI methods can be used to improve the regulatory
environment affecting human subject research with a specific focus on
how data analysis can identify the actionable interdependencies between
different elements of the regulatory environment.
Parameters Selected for Study
In the data collection process, we identified 18 entities at UCSD
with direct influence on the approval of clinical research studies (see
supplementary Figure A for an organizational flow chart). Based
on interviews with the unit directors, we selected the 2 units
perceived to have to most frequent interactions with UCSD IRB:
Office of Coverage Analysis and Office of Contract Analysis (see
supplementary Figure B for a high-level flow chart).
We then interviewed and directly observed researchers applying for
regulatory approval, analyst reviewing these applications and faculty
IRB committee members reviewing new proposals.
Based on this preliminary work and review of the literature, we then
selected data fields from the IRB, Office of Coverage Analysis and Office
of Contract Analysis data management systems for analysis, using ISO
9004:2000 for process and productivity measures, ISO/IEC 15504 for
technology measures and ISO 2859-1 and ANSI/ASQC Z1.9-1993 for
sampling procedures [21, 22]. This amounted to 110 data fields contained
in 8200 IRB, 4200 Coverage Analysis and 350 new contracts submitted
between 2013 and 2016. We constructed and verified data dictionaries
for the data fields followed by data cleaning, verification, and validation
using Cross-Industry Standard Process for Data Mining (CRIP-DM)
methodology [23].
Data Analysis
Following data cleaning, verification, and validation procedures, the
next step in analyzing interdependencies is to explore the distribu-
tional characteristics of the data elements. This is an often overlooked
but critical QI step or, when done, non-normally distributed data are
“normalized” by removing outliers. INCOSE QI uses the distribution
family to select appropriate statistical techniques and explores
“outliers” as “special cause” or “assignable cause” of undesirable
performance variation requiring separate analysis and interventions
[24]. As part of our QI effort, we developed predictive models of
outliers using 2013–2015 data to “predict” 2016 performance data to
assess the stability of the factors creating “outliers” to help determine
the feasibility of, first identifying new proposals likely to become
outliers and, then, providing a more interventional path to help the
investigators address likely challenges in acquiring reserving regulatory
approval in a timely manner.
Statistical Methods
Following INCOSE methodology, non-normally distributed data are
reported using quintile regression, such as Kruskal-Wallis ANOVA,
and predictive analytics [25, 26] with the direction and dispersion of
the data best represented as medians, 25th and 75th percentiles [27].
“Outliers” were analyzed using K-Means and Tree Clustering data
mining techniques. Both data mining techniques can be used when
there is a mixture of Gaussian distributions.
Results
Time Required for IRB Approval
In total, 3389 new human subject research protocols, including 618
commercial sponsored studies, submitted to the UCSD IRB Regu-
latory Environment (IRB environment) between January 2013 and
December of 2014 were used for baseline analysis and modeling
characteristics affecting time to approval. The first step in the INCOSE
methodology was to determine the distribution family, which proved
to be a bounded Johnson Distribution with a highly skewed right-sided
tail for IRB approval times (Fig. 1). The highly skewed right-sided tail is
composed of statistically significant “outliers” identified using Tukey
one-sided test (p= 0.0001). Further analyzing outliers creates an
opportunity to identify variations affecting performance that might
benefit from a change in the workflow [28–31]. Outliers were inde-
pendently identified for 2 key phases of the approval process:
(1) administrative review by staff; and (2) IRB committee review
(see below).
Contribution of Ancillary Reviews to Delays
Both the type and number of ancillary reviews affect the time required
to receive IRB regulatory approval (Fig. 2) (p< 0.0001). Ancillary
reviews also added a median of 36 days (interquartile= 19–64) post
IRB committee approval for release of the consent form. Of
interest, UCSD proposals undergo more ancillary reviews than
many comparable institutions [11]. For example, UCSD phase III multi-
site studies had a median of 3 ancillary reviews (interquartile= 2–4)
whereas data from the previous UC-wide study showed that other
UC campuses operating under the same university policy had a
median of 0.9 reviews (interquartile= 0.2–1.5). The most commonly
co-occurring ancillary reviews at UCSD during the initial review
period were Radiation Safety Committee (50% of the time) and
Scientific Review Committee (35% of the time). The ancillary reviews
associated with the longest approval times were the Scientific Review
Committee (median= 120 days, interquartile= 62–147), Biosafety
Committee (median= 118 days, interquartile= 70–148), and
Radiation Safety (median= 116 days, interquartile= 83–147).
Contribution of Study Type and Study
Misclassification
Unexpectedly, non-interventional applications such as anonymized
registries, retrospective chart reviews, or observational studies had
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longer approval times then interventional clinical trials. In exploring
where delays occurred, the administrative review had a median dura-
tion of 23 days while committee review required a median of 104 days
(p= 0.0018). This counter-intuitive observation is similar to findings
from other investigators [29]. Focus groups conducted with
researchers suggested that the explanation related to researchers not
understanding the criteria and documentation requirements non-
interventional studies. This led to requests for expedited reviews or
requests for exemptions when full IRB review was required. In addi-
tion, 63% of non-interventional studies indicated in the submission
documentation that the protocol was a clinical trial, which also created
administrative delays.
Contribution of Staffing Ratios
Our previous study across the University of California identified IRB
staffing ratios were critical determinants of approval times [11]. This
finding was confirmed with the larger UCSD data set, where static full-
time employee (FTE) staffing over time in the face of increasing num-
ber of new applications changed the ratio of new applications per FTE
from 69:1 in 2013 to 72:1 in 2016 (see supplementary Table C). The
increasing ratio of new protocols to FTEs was accompanied by a rise of
median administrative time from 13 days (interquartile= 6–34) in
2013 to 25 days (interquartile= 15–50) in 2016 (p< 0.0001).
Increased administrative review times meant overall approval times
remained essentially static with a median of 75 days (interquartile=
42–122) in 2013 to a median of 86 days (Interquartile= 53–126) in
2016 (Fig. 3). The increased durations were accompanied by an
increase in the number of withdrawn applications, largely due to delays
for commercial sponsored studies when deadlines passed. For exam-
ple, 9 IRB and 23 contracts were withdrawn in 2013. That number
increased to 43 IRB and 68 contract withdrawals in 2014 (p< 0.001,
p= 0.0182, respectively).
Contribution of Individual Committee Performance
The second operational issue was statistically significant difference
between IRB committees. Comparisons were restricted to Phase III
multisite commercially sponsored clinical trials to control for study
type (see supplementary Figure D). The median time for review
and approval for one committee at 53 days (interquartile= 25–89)
was statistically significantly longer than the other committees
(p= 0.0036). Evaluation of the workflow revealed that the delays were
due to duplicate scientific review for these studies even though
protocols for commercial sponsored studies cannot be altered and
have undergone extensive regulatory review at the U.S. Food and
Drug Administration. To resolve this issue, additional training as well
as performance metrics of each committee were provided to the
committee chairs with the longest timelines. Subsequent follow-up
analysis showed that the timelines matched the other committees with
identical median times for phase III multisite studies.
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Fig. 2. Statistically significant relationship between number of ancillary
reviews and time to Institutional Review Boards (IRB) approval.
Time to Complete Submission 
Time to Complete Committee Review 
Time to Full Approval 
Fig. 1. Distribution of protocol time for approval for administrative review,
committee review and full approval. Vertical axis shows number of protocols
and horizontal axis shows number of days for approval.
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Contribution of Outside Entities and Contract
Office Staffing
Commercial clinical trial sponsors frequently use contract research
organizations (CROs) to negotiate contracts and launch a study.
Contract delays are translated into delays in IRB ICF release and are
typically viewed by the research unit as an “IRB delay.” One of the
most striking finding was that individual CROs varied dramatically in
terms of timeliness of contracting despite the fact that they all work
with the same university contracting office. Fig. 4 shows that there is
wide variation in contract execution for various CROs, typically rela-
ted to responses to queries and contract terms. In addition, Fig. 3
shows how improved staffing and training significantly decreased
overall timelines for contracting.
Contribution of Coverage Analysis
A coverage analysis for protocols that could involve third-party payers,
like defined contract language, is required before the ICF is released.
Although the early days of centralized coverage analyses created sig-
nificant delays, improved staffing ratios and training led to a dramatic
decrease in the time for completing coverage analyses (Fig. 3,
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Fig. 3. Statistically significant changes in contracting, coverage analysis, and
Institutional Review Boards (IRB) approval times. Contracting and coverage
analysis performance has improved since 2014. IRB timelines have modestly
increased primarily due to static staffing ratios.
Fig. 4. Variance in time for contract execution varies for different contract
research organizations (CROs). Each horizontal line represents one CRO for
whom at least 4 contracts were negotiated.
Fig. 5. Statistically significant relationship between study characteristics and
likelihood of a study being an outlier. Comparison with all studies (All) shows that
certain study characteristics can substantially increase the time for completing
approval. IND, Investigational New Drug Application: PI, principal investigator.
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p= 0.0035). An additional policy change at UCSD delegated authority
to the coverage analysis office rather than the research unit to assign a
procedure as billable to third parties or the sponsor. This change
minimized prolonged negotiations with most research units, which can
decline a study if the approved coverage analysis is not acceptable to
that unit. An additional finding is the number of study arms within a
proposal affects the time required to complete coverage analysis
(p= 0.0006). Each arm requires a separate coverage analysis, which
accounts for the longer timelines (see supplementary Figure E).
Identifying Outliers to Improve Regulatory
Performance
Analysis of study characteristics for outliers, defined as observations
which fall more than 1.5 times the interquartile range, shows some of
the key distinguishing features, including principal investigator (PI)-
initiated studies, radiation safety review, and testing devices (Fig. 5).
We further explored study characteristics associated with the 2 major
stages comprising the total approval process: staff review and com-
mittee review times. Staff review outliers have a higher percent of
scientific reviews, new faculty as the PI, vulnerable populations as
research subjects and requests for “reliance” on an external IRB. An
example of one “clustering” of study characteristics likely to become
an outlier is a PI-initiated study submitted by junior faculty member
involving incarcerated juveniles. Another example would be a junior
faculty member submitting a cancer study that would include reliance
on another institution’s IRB review and approval.
Committee outliers were disproportionately comprised of unfunded
studies, PI-initiated studies with protocols requiring radiation, scien-
tific and conflict of interest reviews. An example would be a PI-initiated
cancer study in which the investigator had a potential conflict of
interest, where treatment of metastatic disease was guided by genomic
data and included radiation therapy
Algorithm to Identify Outliers
The outlier data were used to develop an algorithm
ak bk 22
P
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to identify studies with a high probability of
significantly delayed approval. To confirm the approach, we the used
K-Means and Tree Clustering to identify subgroupings that were in
turn used to create Random Forest predictive algorithms. Table 1
shows the key elements that contribute to outlier status for adminis-
trative review, committee review, and total time for approval. The
predictive algorithms were then tested against 3828 study protocols
submitted to the IRB in 2015–2016. The predictive algorithms identi-
fied 88% of the administrative outliers and 93% of the committee
outliers (see Fig. 6).
Overall Impact
While it is difficult to ascribe overall improvement to any one initiative,
improved education, staffing ratios, and policies together contributed
to significant improvement in the performance of the UCSD IRB
environment between the 2013–2014 baseline compared with 2015–
2016. The impact was particularly evident in contracting and coverage
analysis timelines (Fig. 3). However, IRB approval times have modestly
increased. This was largely due to the increased in applications per
FTE discussed earlier (Contribution of Staffing Ratios section) and
has recently been addressed by increasing the staffing for the IRB
administrative office.
Discussion
In this study, we evaluated IRB performance in the context of a larger
regulatory environment that not only includes the IRB but also
ancillary reviews, clinical trial contracting and research billing coverage
analysis. The interactions between the various regulatory units and
the researchers trying to navigate them are dynamic and subject to
Table 1. Random Forest accuracy in predicting 2015–2016 Institutional Review
Boards administrative outliers and committee review outliers
Predictor importance
Response: outlier
Variable
Rank Importance
Institutional Review Boards administrative outliers
Scientific Review Committee required 100 1.000
Junior faculty 99 0.987
Vulnerable population 97 0.965
Reliance 32 0.315
Medicare billing/coverage analysis required 21 0.208
Biosafety Review required 18 0.177
PI-authored 7 0.0666
Predicted
Actual Yes (%) No (%)
Yes 88.1 11.90
No 14.75 85.25
Overall accuracy 85.98 85.98
Predictor importance
Variable
Rank
Importance
Committee review outliers
Number of ancillary reviews required 100 1.000
Conflict of Interest Review Required 58 0.581
Unfunded 57 0.573
Medicare billing/coverage analysis required 52 0.516
Biosafety Review required 46 0.463
Scientific Review Committee required 16 0.157
Oncology/Hematology 15 0.153
Radiation Safety Review required 12 0.115
PI-authored 2 0.0244
Predicted
Actual Yes (%) No (%)
Yes 100.00 0.00
No 100.00 0.00
Overall accuracy 93.90 93.90
PI, principal investigator.
Fig. 6. Correlation between predicted and actual times for IRB approval.
The algorithm to predict outliers (Table 1) was tested against an independent
dataset and showed a significant correlation.
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misinterpretation of data. The IRB often bears the ultimate “blame” for
delays in the eyes of the investigator even though the committees often
are awaiting ancillary reviews, contracts, and coverage analysis simply
because the final common pathway for all delays is ICF release.
One important caveat is that “speed” is not always the optimal
outcome. In some cases, serious contract issues need to be resolved
or the protocol might not incorporate sufficient power or scientific
rigor. These situations might require a pause or delay in order to
assure compliance or an improved risk:benefit profile. However,
operational inefficiencies, such as improper staffing ratios or training,
duplicate reviews, or unnecessary ancillary reviews are clearly areas
that can be addressed. Collaboration between regulatory units and
incorporation of simple solutions like proper staffing, training, project
management, and sharing information between regulatory units can
overcome some of these barriers.
We have also developed an algorithm for predicting outliers, which
can be used to remove those protocols from the normal workflow.
Key study characteristics, including multiple ancillary reviews for IRB,
multiple study arms for coverage analysis (especially in cancer) and
specific CROs for contracting, can be proactively identified. Ultimately
separate workflows could be developed for these protocols, which
could improve the timelines for other protocols because the outliers
will not consume as much resources. Similarly, the causes of adminis-
trative delays can be addressed by maintaining adequate staffing and
assuring research unit education to improve the initial submission.
This systems engineering approach, in which the processes are broken
into individual components, interactions explored and performance
drivers identified, involve exploring methods for improving IRB and
the entire regulatory process. Unfortunately, centralize control
management principles that work in a manufacturing plant are unlikely
to work in a human research regulatory environment. Traditional
systems are managed to minimize cost while human research should
be managed to maximize value. A focus on the efficiency and
productivity of the regulatory units is, as noted above, an important
value but not at the cost of quality, including patient safety.
Rather than mandate a set of interventions or specific outcomes, our
data suggest that a focus on managing complexity by monitoring and
influencing the system state might be more beneficial. The organizing
principle that promotes understanding and/or appreciation of the role
each unit contributes to human research is also required.
A productive approach would be to integrate processes and seek to
learn from each protocol and each delay. For example, minor changes
in protocols (e.g., same protocol with a different drug in a clinical trial)
could be “fast tracked” to assess the safety of the drug rather review
the entire protocol as if it had never been seen before by the IRB or
other offices. Table 2 provides a matrix for exploring the
interdependencies and well as identifying some potential solutions.
The challenges outlined will also be true for a centralized IRB.
Conclusion
We identified and reviewed issues and delays associated with the reg-
ulatory environment, with an emphasis on IRB processes in the context
of a larger regulatory universe. Relatively simple steps can have a sig-
nificant impact on timelines and, ultimately, on researcher satisfaction and
patient access to novel therapies. The next steps will entail analyzing the
impact of these steps on timelines and quality.
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